364 related articles for article (PubMed ID: 35502614)
1. Pharmaceutical policies: effects of regulating drug insurance schemes.
Pantoja T; Peñaloza B; Cid C; Herrera CA; Ramsay CR; Hudson J
Cochrane Database Syst Rev; 2022 May; 5(5):CD011703. PubMed ID: 35502614
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical policies: effects of financial incentives for prescribers.
Rashidian A; Omidvari AH; Vali Y; Sturm H; Oxman AD
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006731. PubMed ID: 26239041
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical policies: effects of educational or regulatory policies targeting prescribers.
Suleman F; Movik E
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31721159
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical policies: effects of cap and co-payment on rational use of medicines.
Luiza VL; Chaves LA; Silva RM; Emmerick IC; Chaves GC; Fonseca de Araújo SC; Moraes EL; Oxman AD
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007017. PubMed ID: 25966337
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
7. Payment methods for healthcare providers working in outpatient healthcare settings.
Jia L; Meng Q; Scott A; Yuan B; Zhang L
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD011865. PubMed ID: 33469932
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical policies: effects of policies regulating drug marketing.
Fulone I; Cadogan C; Barberato-Filho S; Bergamaschi CC; Mazzei LG; Lopes LP; Silva MT; Lopes LC
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013780. PubMed ID: 37288951
[TBL] [Abstract][Full Text] [Related]
9. Financial arrangements for health systems in low-income countries: an overview of systematic reviews.
Wiysonge CS; Paulsen E; Lewin S; Ciapponi A; Herrera CA; Opiyo N; Pantoja T; Rada G; Oxman AD
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011084. PubMed ID: 28891235
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
[TBL] [Abstract][Full Text] [Related]
11. Payment methods for outpatient care facilities.
Yuan B; He L; Meng Q; Jia L
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011153. PubMed ID: 28253540
[TBL] [Abstract][Full Text] [Related]
12. Paying for performance to improve the delivery of health interventions in low- and middle-income countries.
Diaconu K; Falconer J; Verbel A; Fretheim A; Witter S
Cochrane Database Syst Rev; 2021 May; 5(5):CD007899. PubMed ID: 33951190
[TBL] [Abstract][Full Text] [Related]
13. Government regulation of private health insurance.
Motaze NV; Chi PC; Ongolo-Zogo P; Ndongo JS; Wiysonge CS
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD011512. PubMed ID: 33617665
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
[TBL] [Abstract][Full Text] [Related]
15. Patient-initiated appointment systems for adults with chronic conditions in secondary care.
Whear R; Thompson-Coon J; Rogers M; Abbott RA; Anderson L; Ukoumunne O; Matthews J; Goodwin VA; Briscoe S; Perry M; Stein K
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD010763. PubMed ID: 32271946
[TBL] [Abstract][Full Text] [Related]
16. Interventions to reduce corruption in the health sector.
Gaitonde R; Oxman AD; Okebukola PO; Rada G
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008856. PubMed ID: 27528494
[TBL] [Abstract][Full Text] [Related]
17. Taxation of unprocessed sugar or sugar-added foods for reducing their consumption and preventing obesity or other adverse health outcomes.
Pfinder M; Heise TL; Hilton Boon M; Pega F; Fenton C; Griebler U; Gartlehner G; Sommer I; Katikireddi SV; Lhachimi SK
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012333. PubMed ID: 32270494
[TBL] [Abstract][Full Text] [Related]
18. Integrated community case management of childhood illness in low- and middle-income countries.
Oliphant NP; Manda S; Daniels K; Odendaal WA; Besada D; Kinney M; White Johansson E; Doherty T
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD012882. PubMed ID: 33565123
[TBL] [Abstract][Full Text] [Related]
19. Pay for performance for hospitals.
Mathes T; Pieper D; Morche J; Polus S; Jaschinski T; Eikermann M
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD011156. PubMed ID: 31276606
[TBL] [Abstract][Full Text] [Related]
20. Printed educational materials: effects on professional practice and healthcare outcomes.
Giguère A; Zomahoun HTV; Carmichael PH; Uwizeye CB; Légaré F; Grimshaw JM; Gagnon MP; Auguste DU; Massougbodji J
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD004398. PubMed ID: 32748975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
